PUMA BIOTECHNOLOGY, INC. — Operating Income by Fiscal Year
15 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/b38f9edb-828d-4ec4-86d3-058f6b0d23fc/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $37.3M | 2025-01-01 – 2025-12-31 | evidence 0001437749-26-005891 |
| FY 2024 | $31.0M | 2024-01-01 – 2024-12-31 | evidence 0001437749-25-005496 |
| FY 2023 | $32.6M | 2023-01-01 – 2023-12-31 | evidence 0001437749-24-006121 |
| FY 2022 | $23.7M | 2022-01-01 – 2022-12-31 | evidence 0001437749-23-005233 |
| FY 2021 | $1.3M | 2021-01-01 – 2021-12-31 | evidence 0001437749-22-005164 |
| FY 2020 | $-30.4M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-009840 |
| FY 2019 | $-39.0M | 2019-01-01 – 2019-12-31 | evidence 0001564590-21-009840 |
| FY 2018 | $-94.7M | 2018-01-01 – 2018-12-31 | evidence 0001564590-21-009840 |
| FY 2017 | $-292.4M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-005152 |
| FY 2016 | $-276.6M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-003090 |
| FY 2015 | $-240.3M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-013716 |
| FY 2014 | $-142.3M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-001193 |
| FY 2013 | $-159.3M | 2010-09-16 – 2014-03-31 | evidence 0001193125-14-194791 |
| FY 2012 | $-96.4M | 2010-09-16 – 2013-03-31 | evidence 0001193125-13-211141 |
| FY 2011 | $-22.0M | 2010-09-15 – 2012-03-31 | evidence 0001193125-12-234886 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).